Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Optimisation of breast cancer patients’ follow- up – potential way to improve cancer care in transitional countries. (CROSBI ID 264358)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Bošković, Lidija ; Gašparić, Maja ; Petrić Miše, Branka ; Petković, Marija ; Gugić, Damir ; Ban, Marija ; Jazvić, Marijana ; Dabelić, Nina ; Belac Lovasić, Ingrid ; Vrdoljak, Eduard Optimisation of breast cancer patients’ follow- up – potential way to improve cancer care in transitional countries. // European journal of cancer care, 26 (2017), 4; 12514, 7. doi: 10.1111/ecc.12514

Podaci o odgovornosti

Bošković, Lidija ; Gašparić, Maja ; Petrić Miše, Branka ; Petković, Marija ; Gugić, Damir ; Ban, Marija ; Jazvić, Marijana ; Dabelić, Nina ; Belac Lovasić, Ingrid ; Vrdoljak, Eduard

engleski

Optimisation of breast cancer patients’ follow- up – potential way to improve cancer care in transitional countries.

The aim of this analysis was to evaluate adherence of Croatian oncologists to follow‐up criteria as suggested by the current national and international guidelines for women with breast cancer receiving adjuvant endocrine therapy. The use of clinical and diagnostic methods was documented in this prospective, non‐ interventional, multicenter study. A total of 438 post‐menopausal patients receiving adjuvant endocrine treatment with non‐steroidal aromatase inhibitors were included. Average annual frequency for each clinical and diagnostic method was calculated. Median adjuvant endocrine treatment duration before study recruitment was 10.5 months (interquartile 4.7–26.6). Patients were followed up for an average 23.5 ± 4.9 months. Average number of oncological visits was 5.3. Mammograms were performed at mean annual frequency of 0.7, chest radiographs at 0.5, abdominal ultrasounds at 0.9, breast ultrasounds at 1.2, complete blood counts and chemistry panels at 1.7, carcinoembryonic antigen at 0.8, cancer antigen 15‐3 at 1.6, gynaecological examination at 0.3, and densitometry at mean annual frequency of 0.3. In conclusion, among post‐menopausal women with breast cancer receiving adjuvant endocrine therapy in this study, more unnecessary and unproven follow‐up procedures were done compared to the guidelines' recommendations.

breast cancer ; adjuvant hormonal therapy ; follow up ; diagnostic procedures ; aromatase inhibitors

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

26 (4)

2017.

12514

7

objavljeno

0961-5423

1365-2354

10.1111/ecc.12514

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost